Nurix Therapeutics (NRIX) AI Stock Analysis

• Market Cap: $773.03M
• Dividend Yield: N/A
• Average Volume (3M): 970.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.20
• Revenue Growth: -30.25%
• EPS Growth: -5.92%
• Country: US
• Employees: 286
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.67
• Shares Outstanding: 76,235,596
• 10 Day Avg. Volume: 812,486
• 30 Day Avg. Volume: 970,202
• PEG Ratio: -1.45
• Price to Book (P/B): 1.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $29.87
• Price Target Upside: 194.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15

• Rating: 47 Neutral
• Price Target: ―

Nurix Therapeutics is currently facing significant financial challenges, particularly in terms of profitability and cash flow sustainability. The stock's technical indicators suggest ongoing downward pressure, and valuation metrics are unattractive due to negative earnings. Although a recent positive corporate development could aid future potential, it does not offset the immediate financial and operational concerns.

Positive Factors

Clinical Trials

NRIX remains on track to commence a series of clinical trials to support global registration of Bexo in CLL.

Collaborations

Nurix received $18.5M in collaboration revenue in 1Q:25 and an additional $15M license extension fee from Sanofi after the quarter ended.

Financial Position

The company maintains a strong cash position (~$550M) with runway into 1H:27.

Negative Factors

Competition

There is notable competition in the space with ONC's BTK degrader BGB-16673 already advancing in a pivotal Ph 2.

Competitive Landscape

Value creation with bexobrutideg is complicated by the robust competitive landscape and tough development path.

Nurix Therapeutics Business Overview & Revenue Model

Company Description

Nurix Therapeutics, Inc. (NRIX) is a biopharmaceutical company based in the United States that focuses on the discovery, development, and commercialization of therapies targeting the ubiquitin proteasome system. The company operates in the biotechnology sector and primarily develops products that aim to treat cancer and other challenging diseases through the modulation of protein levels using its proprietary drug discovery platform, DELigase. Nurix's core products are in the preclinical and clinical stages of development, targeting various oncology and immuno-oncology indications.

How the Company Makes Money

Nurix Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies. These agreements often include upfront payments, research funding, milestone payments, and potential royalties on sales of products developed through joint efforts. The company leverages its proprietary technology platform to engage in partnerships that enhance its drug discovery capabilities and expand its pipeline. Significant collaborations with leading pharmaceutical companies contribute to its earnings and support the ongoing research and development of its therapeutic candidates.

Nurix Therapeutics Financial Statement Overview

Summary

Nurix Therapeutics faces significant challenges in achieving profitability and sustainable cash flow. The income statement shows negative profitability margins, the balance sheet reflects a strong equity position with minimal leverage, and the cash flow statement highlights ongoing operational and profitability concerns.

Income Statement

Nurix Therapeutics has shown an inconsistent revenue trend with notable fluctuations. The TTM data indicates a gross profit margin of 85.39%, reflecting efficient cost management relative to revenue. However, the company is struggling with profitability, as indicated by a negative net profit margin of -369.41%. EBIT and EBITDA margins are also negative, highlighting ongoing operational challenges.

Balance Sheet

The company displays a strong equity position, with an equity ratio of 78.19% in the TTM, indicating low leverage and a strong reliance on equity financing. However, the debt-to-equity ratio stands at 0.06, which is relatively low, suggesting minimal debt use. Return on Equity (ROE) remains negative due to ongoing net losses, impacting overall financial stability.

Cash Flow

Operating cash flow is negative, reflecting ongoing cash burn from operations. The free cash flow growth rate remains concerning, with continued negative figures indicating challenges in generating cash from operations. However, the operating cash flow to net income ratio is slightly improving, suggesting potential operational efficiency gains.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
56.42M	54.55M	76.99M	38.63M	29.75M	17.82M
	Gross Profit
44.05M	38.12M	-112.16M	27.82M	23.67M	-48.67M
	EBIT
-230.67M	-213.03M	-155.06M	-183.87M	-117.89M	-64.98M
	EBITDA
-214.00M	-196.60M	-141.41M	-173.06M	-111.80M	-62.80M
	Net Income Common Stockholders
-208.40M	-193.57M	-143.95M	-166.04M	-117.19M	-43.24M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
549.68M	609.58M	287.91M	309.14M	295.72M	281.15M
	Total Assets
615.04M	669.34M	355.60M	416.76M	476.77M	396.34M
	Total Debt
26.62M	28.30M	30.61M	11.96M	13.04M	0.00
	Net Debt
-49.29M	-81.69M	-24.01M	-52.51M	-67.47M	-119.36M
	Total Liabilities
134.13M	142.35M	155.10M	113.06M	134.47M	106.07M
	Stockholders Equity
480.92M	526.99M	200.49M	303.70M	342.30M	290.27M
Cash Flow		Free Cash Flow
-201.59M	-181.86M	-89.77M	-172.05M	-90.03M	-4.63M
	Operating Cash Flow
-191.72M	-172.58M	-81.36M	-159.81M	-84.36M	-80.00K
	Investing Cash Flow
-267.69M	-257.71M	68.30M	27.20M	-108.25M	-254.40M
	Financing Cash Flow
485.52M	485.67M	3.22M	117.19M	153.88M	339.02M

Nurix Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Negative. The current price of 10.14 is below the 20-day moving average (MA) of 10.35, below the 50-day MA of 11.07, and below the 200-day MA of 18.89, indicating a bearish trend. The MACD of -0.44 indicates Negative momentum. The RSI at 43.24 is Neutral, neither overbought nor oversold. The STOCH value of 55.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRIX.

Nurix Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	54 Neutral	$938.47M	―	-57.92%	―	-13.37%	2.57%
MLYS	53 Neutral	$998.49M	―	-56.31%	―	―	-106.10%
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%
RCUS	51 Neutral	$922.26M	―	-63.17%	―	-40.51%	-35.07%
ARVN	48 Neutral	$476.63M	―	-35.41%	―	-39.92%	7.38%
NRIX	47 Neutral	$773.03M	―	-64.16%	―	-30.25%	-5.92%
IOVA	39 Underperform	$611.10M	―	-51.85%	―	11070.12%	32.07%

Nurix Therapeutics Corporate Events

Nurix Therapeutics Holds 2025 Annual Stockholders Meeting

On May 19, 2025, Nurix Therapeutics held its virtual 2025 Annual Meeting of Stockholders, where approximately 85.33% of the voting power was represented. Stockholders voted to elect three Class II directors, ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approve the compensation of named executive officers on a non-binding advisory basis.

The most recent analyst rating on (NRIX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.

Nurix Therapeutics Appoints Dr. Roy D. Baynes to Board

On March 11, 2025, Nurix Therapeutics appointed Dr. Roy D. Baynes to its board of directors and as a member of the Clinical and Commercialization Committee. Dr. Baynes, who has extensive experience in hematology and oncology, will contribute to advancing Nurix’s pipeline across oncology and autoimmune indications. His appointment is expected to enhance the company’s clinical development and commercialization efforts, particularly in the face of growing resistance to BTK inhibitors.